BD has added three- and four-laser versions of its FACSDiscover A8 analyzer, offering additional configuration choices for labs using spectral flow cytometry.
BD (Becton, Dickinson and Company) announced the global commercial release of new three- and four-laser configurations of its BD FACSDiscover A8 Cell Analyzer.
The three- and four-laser additions complement the five-laser instrument launched earlier this year, featuring BD SpectralFX Technology for analyzing up to 50 or more characteristics of a single cell and BD CellView Image Technology for high-speed imaging that reveals spatial and morphological insights in real time.
Both versions offer laboratories the option to start with a free trial of CellView Image Technology and upgrade later via software, providing additional flexibility for budget planning and implementation.
“The BD FACSDiscover A8 Cell Analyzer has become our new standard, changing how our flow cytometry core operates,” says Gert Van Isterdael, head of VIB Flow Core Ghent, in a release. “Once you experience the integration of spectral and imaging data, you don’t want to go back. It opens a new dimension for our work, helping us see more, understand faster, and enable discoveries that simply weren’t possible before.”
High-Throughput Automation and Integration
All configurations feature high-throughput, walkaway automation designed to deliver cost-per-insight economics through real-time imaging, according to a release fomr the company. The software manages large datasets and is designed for out-of-the-box standardization.
The analyzers integrate with the BD FACSDiscover Cell Sorter ecosystem and BD Reagents, including the recently launched BD Horizon RealViolet 828 and RealBlue 824 fluorochromes. These near-infrared spectrum fluorochromes can unlock new discoveries through spectral flow cytometry when used with the cell analyzer, according to a release from the company.
The technology is designed to enable scientists to analyze protein location within single cells and other morphological characteristics that traditional flow cytometry cannot detect, supporting research in immunology, cancer immunotherapy, and cell biology.
“In today’s complex research landscape, access to leading-edge technologies through flexibility and modularity is crucial, from basic to translational science,” says Steve Conly, worldwide president of BD Biosciences, in a release. “Alongside the entire BD ecosystem of sorters, reagents, and informatics, the BD FACSDiscover A8 Cell Analyzer continues to be rapidly adopted by leading biopharmaceutical companies, and now with more entry points, organizations of all sizes can access the same technology.”
